Siemens Healthineers

Siemens Healthineers is a German medical-technology company headquartered in Erlangen. Its primary listing is in Frankfurt, with a US depositary receipt quoted over the counter (OTC: SMMNY). It makes computed tomography (CT) and magnetic resonance imaging (MRI) scanners, X-ray and interventional imaging systems and laboratory diagnostics, and since buying Varian in April 2021 for about 16.4 billion dollars it also makes radiation-therapy systems for cancer. It employed about 74,000 people at the end of fiscal 2025. It appears in the catalog not as a pure AI vendor but as a large AI adopter that ships AI inside the hardware and software it sells. It does sell AI software, such as the AI-Rad Companion reading assistants, but through hospital contracts priced by quote rather than as a self-serve product.

Its defining pattern is the embedded-AI device maker: machine learning arrives as a feature of a scanner or a reading workstation, and each feature needs its own regulatory clearance. The US Food and Drug Administration (FDA) publishes a list of the AI-enabled devices it has authorized. As updated in September 2026, that list carries roughly 100 entries under Siemens Healthineers entities, including its Varian unit, second only to GE HealthCare. The AI-Rad Companion family shows the software side. Its first chest CT modules were cleared in September 2019 to flag lung lesions, coronary calcium and aortic findings, and the company designed them to read scans from GE and Philips machines as well as its own.

At the Radiological Society of North America (RSNA) meeting that opened in Chicago on November 30, 2025, it unveiled the syngo.CT Coronary Cockpit, which uses AI-based segmentation and labeling to measure plaque in the heart's arteries before a stent procedure; the FDA list records its clearance in June 2026. It also showed the Magnetom Free.XL, a low-field interventional MRI scanner developed with Cook Medical that pairs a wide bore with Deep Resolve, its deep-learning image reconstruction; the company says that system is still under development and not commercially available. In May 2026 the FDA cleared six Artis interventional systems that share the Optiq AI imaging chain, which applies deep-learning noise reduction to fluoroscopy and angiography in real time.

Ownership is in motion. Siemens AG took the company public in March 2018 and still owned about 67 percent in November 2025, when it announced a plan to hand part of that stake directly to its own shareholders. That same month, Siemens Healthineers set out a strategy called Elevating Health Globally, naming AI an important lever and letting its diagnostics business pursue its own path. In April 2026 Siemens AG said the spin-off vote would come at its February 2027 annual meeting.

The honest framing: Siemens Healthineers' value rests on its installed base of scanners, laboratory analyzers and radiation-therapy machines. AI is a lever on top, and most of it is genuine machine learning, such as denoising, image reconstruction and segmentation, rather than rebranded automation. But an FDA clearance authorizes a device for its stated use; it is not evidence of better patient outcomes, and claims such as sharper images at the same radiation dose are the company's own. Its closest peer is GE HealthCare, which follows the same build-it-into-the-machine pattern with an even longer FDA list. The drugmakers in the catalog, such as Merck & Co. and Novo Nordisk, buy AI from platform vendors to run their businesses, while Siemens Healthineers builds it into what it sells.